Diagnosis and treatment of systemic mastocytosis: State of the art

British Journal of Haematology

Volumn 122, Issue 5, 2003, Pages 695-717

  Valent, Peter ^a   Akin, Cem ^b   Sperr, Wolfgang R ^a   Horny, Hans P ^e   Arock, Michel ^c   Lechner, Klaus ^a   Bennett, John M ^d   Metcalfe, Dean D ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Faculte de Pharmacie   (France)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e NONE

Author keywords

C kit; Classification; Mastocytosis; Mediator symptoms; Tryptase

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIHISTAMINIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN D2; PROTON PUMP INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

BONE MARROW; CELL INFILTRATION; CELL STRUCTURE; CHEMOTHERAPY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LABORATORY TEST; MAST CELL; MAST CELL LEUKEMIA; MEDIATOR RELEASE; MONITORING; PATIENT SELECTION; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; SYSTEMIC MASTOCYTOSIS;

ACUTE DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PROGNOSIS;

EID: 0041411106     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04575.x     Document Type: Review

References (169)

1. Agis, H., Willheim, M., Sperr, W.R., Wilfing, A., Krömer, E., Kabrna, E., Spanblöchl, E., Strobl, H., Geissler, K., Spittler, A., Zsebo, K.M., Boltz-Nitulescu, G., Lechner, K. & Valent, P. (1993) Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony forming cell. Journal of Immunology, 151, 4221-4227.
2. Agis, H., Füreder, W., Bankl, H.C., Kundi, M., Sperr, W.R., Willheim, M., Boltz-Nitulescu, G., Butterfield, J.H., Kishi, K., Lechner, K. & Valent, P. (1996) Comparative immunophenotypic analysis of human mast cells, blood basophils, and monocytes. Immunology, 87, 535-543.
3. Akin, C. & Metcalfe, D.D. (2002) Surrogate markers of disease in mastocytosis. International Archives of Allergy and Immunology, 127, 133-136.
4. Akin, C., Kirshenbaum, A.S., Semere, T., Worobec, A.S., Scott, L.M. & Metcalfe, D.D. (2000a) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Experimental Hematology, 28, 140-147.
5. Akin, C., Schwartz, L.B., Kitoh, T., Obayashi, H., Worobec, A.S., Scott, L.M. & Metcalfe, D.D. (2000b) Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood, 96, 1267-1273.
6. Akin, C., Scott, L.M. & Metcalfe, D.D. (2001) Slowly progressive systemic mastocytosis with high mast cell burden and no evidence of a non-mast cell hematologic disorder. An example of a smoldering case? Leukemia Research, 25, 635-638.
7. Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, J. & Metcalfe, D.D. (2003) Effects of the tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology, 31, 686-692.
8. Alexander, R.R. (1985) Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. Acta Haematologica, 74, 108-110.
9. Austen, K.F. (1992) Systemic mastocytosis. New England Journal of Medicine, 326, 639-640.
10. Back, J.Y., Li, C.Y., Pardanani, A., Butterfield, J.H. & Tefferi, A. (2002) Bone marrow angiogenesis in systemic mast cell disease. Journal of Hematotherapy and Stem Cell Research, 11, 139-146.
11. Benyon, R.C., Lowman, M.A. & Church, M.K. (1987) Human skin mast cells: their dispersion, purification, and secretory characterization. Journal of Immunology, 138, 861-867.
12. Biedermann, T., Rueff, F., Sander, C.A. & Przybilla, B. (1999) Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. British Journal of Dermatology, 141, 1110-1112.
13. Borgeat, A. & Ruetsch, Y.A. (1998) Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesthesiology and Analgetics, 86, 442-444.
14. Brockow, K., Scott, L.M., Worobec, A.S., Kirshenbaum, A., Akin, C., Huber, M.M. & Metcalfe, D.D. (2002) Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Archives of Dermatology, 138, 785-790.
15. Burd, P.R., Rogers, H.W., Gordon, J.R., Martin, C.A., Jayaraman, S., Wilson, S.D., Dvorak, A.M., Gallsi, S.J. & Dorf, M.E. (1989) Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. Journal of Experimental Medicine, 170, 245-257.
16. Butterfield, J.H. (1998) Response of severe systemic mastocytosis to interferon alpha. British Journal of Dermatology, 138, 489-495.
17. Buttner, C., Henz, B.M., Welker, P., Sepp, N.T. & Grabbe, J. (1998) Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. Journal of Investigative Dermatology, 111, 1227-1231.
18. Casassus, P., Caillat-Vigneron, N., Martin, A., Simon, J., Gallais, V., Beaudry, P., Eclache, V., Laroche, I., Lortholary, P., Raphael, M., Guillevin, L. & Lortholary, O. (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicenter phase II trial on 20 patients. British Journal of Haematology, 119, 1090-1097.
19. Castells, M. & Austen, K.F. (2002) Mastocytosis: mediator-related signs and symptoms. International Archives of Allergy and Immunology, 127, 147-152.
20. Chosidow, O., Becherel, P.A., Piette, J.C., Arock, M., Debre, P. & Frances, C. (1998) Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-alpha and efficacy of interferon-alfa. British Journal of Dermatology, 138, 698-703.
21. Christophers, E., Hönigsmann, H., Wolff, K. & Langner, A. (1978) PUVA-treatment of urticaria pigmentosa. British Journal of Dermatology, 98, 701-702.
22. Czarnetzki, B.M., Rosenbach, T., Kolde, G. & Frosch, P.J. (1985) Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Archives of Dermatological Research, 277, 105-113.
23. Daeron, M., Sterk, A.R., Hirata, F. & Ishizaka, T. (1982) Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. Journal of Immunology, 129, 1212-1218.
24. Dalton, R., Chan, L., Batten, E. & Eridani, S. (1986) Mast cell leukemia: evidence for bone marrow origin of the pathological clone. British Journal of Haematology, 64, 397-406.
25. Delaporte, E., Pierard, E., Wolthers, B.G., Desreumaux, P., Janin, A., Cortot, A., Piette, F. & Bergoend, H. (1995) Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. British Journal of Dermatology, 132, 479-482.
26. Dolovich, J., Punthakee, N.D., MacMillan, A.B. & Osbaldeston, G.J. (1974) Systemic mastocytosis: control of lifelong diarrhea by ingested disodium cromoglycate. Canadian Medical Association Journal, 111, 684-685.
27. Eklund, K.K., Humphries, D.E., Xia, Z., Ghildyal, N., Friend, D.S., Gross, V. & Stevens, R.L. (1997) Glucocorticoids inhibit the cytokine-induced proliferation of mast cells, the high-affinity IgE receptor-mediated expression of TNF-α, and the IL-10-induced expression of chymases. Journal of Immunology, 158, 4373-4380.
28. Escribano, L., Orfao, A., Diaz-Agustin, B., Villarrubia, J., Cervero, C., Lopez, A., Marcos, M.A., Bellas, C., Fernandez-Canadas, S., Cuevas, M., Sanchez, A., Velascos, J.L., Navarro, J.L. & Miguel, J.F. (1998) Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implication. Blood, 91, 2731-2736.
29. Escribano, L., Díaz-Agustín, B., Bellas, C., Navalón, R., Nuñez, R., Sperr, W.R., Schernthaner, G.H., Valent, P. & Orfao, A. (2001) Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leukemia Research, 25, 563-570.
30. Escribano, L., Akin, C., Castells, M., Orfao, A. & Metcalfe, D.D. (2002a) Mastocytosis: current concepts in diagnosis and treatment. Annals of Hematology, 81, 677-690.
31. Escribano, L., Pérez de Oteyza, J., Núnez, R. & Orfao, A. (2002b) Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: report of a case of mastocytosis associated with a lymphoplasmocytic lymphoma. Leukemia Research, 26, 1043-1046.
32. Feger, F., Ribadeau Dumas, A., Leriche, L., Valent, P. & Arock, M. (2002) Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. International Archives of Allergy and Immunology, 127, 110-114.
33. Fiehn, C., Prummer, O., Gallati, H., Heilig, B. & Hunstein, W. (1995) Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. European Journal of Clinical Investigation, 25, 615-618.
34. Finotto, S., Mekori, Y.A. & Metcalfe, D.D. (1987) Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. Journal of Clinical Investigation, 99, 1721-1728.
35. Floman, Y. & Amir, G. (1991) Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. Journal of Spinal Disorders, 4, 369-373.
36. Födinger, M., Fritsch, G., Winkler, K., Emminger, W., Mitterbauer, G., Gadner, H., Valent, P. & Mannhalter, C. (1994) Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood, 84, 2954-2959.
37. Fricker, M., Helbling, A., Schwartz, L. & Muller, U. (1997) Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. Journal of Allergy and Clinical Immunology, 100, 11-15.
38. Friedman, B., Darling, G., Norton, J., Hamby, L. & Metcalfe, D.D. (1990) Splenectomy in the management of systemic mast cell disease. Surgery, 107, 94-100.
39. Frieri, M., Alling, D.W. & Metcalfe, D.D. (1985) Comparison of the therapeutic efficacy or cromolyn sodium with that of combined chlorphenidramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. American Journal of Medicine, 78, 9-14.
40. Fritsche-Polanz, R., Jordan, J.H., Feix, A., Sperr, W.R., Sunder-Plassmann, G., Valent, P. & Födinger, M. (2001) Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. British Journal of Haematology, 113, 357-364.
41. Fukuda, T., Kamashima, T., Tsuura, Y., Suzuki, T., Kakihara, T., Naito, M., Kishi, K., Matsumoto, K., Shibata, A. & Seito, T. (1995) Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia. Journal of Pathology, 177, 139-146.
42. Galli, S.J. (1990) Biology of disease: new insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Laboratory Investigations, 62, 5-33.
43. Galli, S.J., Tsai, M. & Wershil, B.K. (1993) The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. American Journal of Pathology, 142, 965-974.
44. Gasior-Chrzan, B. & Falk, E.S. (1992) Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists. Dermatology, 184, 149-152.
45. Godt, O., Proksch, E., Steit, V. & Christophers, E. (1997) Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology, 195, 35-39.
46. Goins, V.A. (1991) Mastocytosis. Perioperative considerations. AORN Journal, 54, 1227-1238.
47. Gordon, J.R. & Galli, S.J. (1990) Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature, 346, 274-276.
48. Gordon, J.R., Burd, P.R. & Galli, S.J. (1990) Mast cells as a source of multifunctional cytokines. Immunology Today, 11, 458-464.
49. Greenblatt, E.P. & Chen, L. (1990) Urticaria pigmentosa: an anesthetic challenge. Journal of Clinical Anesthesiology, 2, 108-115.
50. Günther, P.P., Huebner, A., Sobottka, S.B., Neumeister, V., Weissbach, G., Todt, H. & Parwaresch, M.R. (2001) Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. Journal of Pediatric Hematology and Oncology, 23, 134-138.
51. Hartmann, K. & Henz, B.M. (2002) Cutaneous mastocytosis -clinical heterogeneity. International Archives of Allergy and Immunology, 127, 143-146.
52. Hartmann, K., Bruns, S.B. & Henz, B.M. (2001) Mastocytosis: review of clinical and experimental aspect. Journal of Investigative Dermatology Symposium Proceedings, 6, 143-147.
53. Hauswirth, A., Sperr, W.R., Jordan, J.-H., Ghannadan, M., Schernthaner, G.-H., Lechner, K. & Valent, P. (2002) A case of smouldering mastocytosis with lymphadenopathy and eosinophilia. Leukemia Research, 26, 601-606.
54. Horan, R.F. & Austen, K.F. (1991) Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. Journal of Investigative Dermatology, 96, 5S-13S.
55. Horan, R.F., Scheffer, A.L. & Austen, K.F. (1990) Cromolyn sodium in the management of systemic mastocytosis. Journal of Allergy and Clinical Immunology, 85, 852-855.
56. Horny, H.-P. & Valent, P. (2001) Diagnosis of mastocytosis: general histo-pathological aspects, morphological criteria, and immunohistochemical findings. Leukemia Research, 25, 543-551.
57. Horny, H.-P. & Valent, P. (2002) Histopathological and immunocytochemical aspects of mastocytosis. International Archives of Allergy and Immunology, 127, 115-117.
58. Horny, H.-P., Parwaresch, M.R. & Lennert, K. (1985) Bone marrow findings in systemic mastocytosis. Human Pathology, 16, 808-814.
59. Horny, H.-P., Parwaresch, M.R., Kaiserling, E., Müller, K., Olbermann, M., Mainzer, K. & Lennert, K. (1986) Mast cell sarcoma of the larynx. Journal of Clinical Pathology, 39, 596-602.
60. Horny, H.-P., Kaiserling, E., Campbell, M., Parwaresch, M.R. & Lennert, K. (1989) Liver findings in generalized mastocytosis. A clinicopathologic study. Cancer, 63, 532-538.
61. Horny, H.-P., Ruck, M., Wehrmann, M. & Kaiserling, E. (1990a) Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. British Journal of Haematology, 76, 186-193.
62. Horny, H.-P., Schaumberg-Lever, G., Bolz, S., Geerts, M.L. & Kaiserling, E. (1990b) Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells. Journal of Clinical Pathology, 43, 719-722.
63. Horny, H.-P., Ruck, M. & Kaiserling, E. (1992a) Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer, 70, 459-468.
64. Horny, H.-P., Kaiserling, E., Parwaresch, M.R. & Lennert, K. (1992b) Lymph node findings in generalized mastocytosis. Histopathology, 21, 439-446.
65. Horny, H.-P., Ruck, P., Xiao, J.C. & Kaiserling, E. (1993) Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Human Pathology, 24, 355-358.
66. Horny, H.-P., Sillaber, C., Menke, D., Kaiserling, E., Wehrmann, M., Stehberger, B., Chott, A., Lechner, K., Lennert, K. & Valent, P. (1998) Diagnostic value of immunostaining for tryptase in patients with mastocytosis. American Journal of Surgical Pathology, 22, 1132-1140.
67. Irani, A.M., Nilsson, G., Miettinen, U., Craig, S.S., Ashman, L.K., Ishizaka, T. & Schwartz, L.B. (1992) Recombinant human stem cell factor stimulates differentiation of human mast cells from dispersed fetal liver cells. Blood, 80, 3009-3016.
68. Ishizaka, T. & Ishizaka, K. (1984) Activation of mast cells for mediator release through IgE receptors. Progress in Allergy, 34, 188-235.
69. James, P.D., Krafchik, B.R. & Johnston, A.E. (1987) Cutaneous mastocytosis in children: anaesthetic considerations. Canadian Journal of Anaesthesiology, 34, 522-524.
70. Jordan, J.-H., Fritsche-Polanz, R., Sperr, W.R., Mitterbauer, G., Födinger, M., Schernthaner, G.H., Bankl, H.C., Gebhart, W., Chott, A., Lechner, K. & Valent, P. (2001a) A case of smouldering mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leukemia Research, 25, 627-634.
71. L. Human Pathology, 32, 545-552.
72. Jordan, J.H., Schernthaner, G.H., Fritsche-Polanz, R., Sperr, W.R., Födinger, M., Chott, A., Geissler, K., Lechner, K., Horny, H.-P. & Valent, P. (2002) Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria. Leukemia and Lymphoma, 43, 575-582.
73. Kempuraj, D., Saito, H., Kaneko, A., Fukagawa, K., Nakayama, T., Toru, H., Tomikawa, M., Tachimoto, H., Ebisawa, M., Akasawa, A., Miyagi, T., Kimura, H., Nakajima, T., Tsuji, K. & Nakahata, T. (1999) Characterization of the mast cell-committed progenitors present in human umbilical cord blood. Blood, 93, 3338-3346.
74. Kirshenbaum, A.S., Goff, J.P., Kessler, S.W., Mican, J.M., Zsebo, K.M. & Metcalfe, D.D. (1992) Effects of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. Journal of Immunology, 148, 772-777.
75. Kirshenbaum, A.S., Goff, J.P., Semere, T., Foster, B., Scott, L.M. & Metcalfe, D.D. (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood, 94, 2333-2342.
76. Kitamura, Y., Yokoyama, M., Matsuda, H., Ohno, T. & Mori, K.J. (1981) Spleen colony forming cell as common precursor for tissue mast cells and granulocytes. Nature, 291, 159-160.
77. Kluin-Nelemans, H.C., Jansen, J.H., Breukelman, H., Wolthers, B.G., Kluin, P.M., Kroon, H.M. & Willemze, R. (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. New England Journal of Medicine, 326, 619-623.
78. Kojima, M., Nakamura, S., Itoh, H., Ohno, Y., Masawa, N., Joshita, T. & Suchi, T. (1999) Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Modern Pathology, 12, 739-743.
79. Kolde, G., Frosch, P.J. & Czarnetzki, B.M. (1984) Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphological, ultrastructural, and biochemical investigations. Journal of Investigative Dermatology, 83, 175-178.
80. Kyriakou, D., Kouroumalis, E., Konsolas, J., Oekonomaki, H., Tzardi, M., Kanavaros, P., Manoussos, O. & Eliopoulos, G.D. (1998) Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis - report of four cases. American Journal of Gastroenterology, 93, 106-108.
81. Lawrence, I.D., Warner, J.A., Cohan, V.L., Hubbard, W.C., Kagey-Sobotka, A. & Lichtenstein, L.M. (1987) Purification and characterization of human skin mast cells, evidence for mast cell heterogeneity. Journal of Immunology, 139, 3062-3069.
82. Lawrence, J.B., Friedman, B.S., Travis, W.D., Chinchilli, V.M., Metcalfe, D.D. & Gralnick, H.R. (1991) Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. American Journal of Medicine, 91, 612-624.
83. Lehmann, T., Beyeler, C., Lammle, B., Hunziker, T., Vock, P., Olah, A.J., Dahinden, C. & Gerber, N.J. (1996) Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. British Journal of Rheumatology, 35, 898-900.
84. Lennert, K. & Parwaresch, M.R. (1979) Mast cells and mast cell neoplasia: a review. Histopathology, 3, 349-365.
85. Lerno, G., Slaats, G., Coenen, E., Herregods, L. & Rolly, G. (1990) Anaesthetic management of systemic mastocytosis. British Journal of Anaesthesiology, 65, 254-257.
86. Lewis, R.A. & Austen, K.F. (1981) Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature, 293, 103-108.
87. Li, C.-Y. (2001) Diagnosis of mastocytosis: value of cytochemistry and immuno-histochemistry. Leukemia Research, 25, 537-541.
88. Li, W.V., Kapadia, S.B., Sonmez-Alpan, E. & Swerdlow, S.H. (1996) Immuno-histochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Modern Pathology, 9, 982-988.
89. Liao, A.T., Chien, M.B., Shenoy, N., Mendel, D.B., McMahon, G., Cherriongton, J.M. & London, C.A. (2002) Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood, 100, 585-593.
90. Longley, B.J., Tyrrell, L., Lu, S.Z., Ma, Y.S., Langley, K., Ding, T.G., Duffy, T., Jacobs, P., Tang, L.H. & Modlin, I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics, 12, 312-314.
91. Longley, B.J., Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D. & Ma, Y. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the USA, 96, 1609-1614.
92. Longley, B.J., Regura, M.J. & Ma, Y. (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research, 25, 571-576.
93. Ma, Y., Zeng, S., Metcalfe, D.D., Akin, C., Dimitrijevic, S., Butterfield, J.H., McMahon, G. & Longley, B.J. (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzyme site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 99, 1741-1744.
94. Marone, G. & Stellato, C. (1992) Activation of human mast cells and basophils by general anaesthetic drugs. Monograph Allergy, 30, 54-73.
95. Marone, G., Spadaro, G., Granata, F. & Triggiani, M. (2001) Treatment of mastocytosis: pharmacologic basis and current concepts. Leukemia Research, 25, 583-594.
96. Metcalfe, D.D. (1991a) Classification and diagnosis of mastocytosis: current status. Journal of Investigative Dermatology, 96, 2S-4S.
97. Metcalfe, D.D. (1991b) The liver, spleen, and lymph nodes in mastocytosis. Journal of Investigative Dermatology, 96, 45S-46S.
98. Metcalfe, D.D. (1991c) The treatment of mastocytosis: an overview. Journal of Investigative Dermatology, 96, 55S-59S.
99. Metcalfe, D.D. (2000) Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy and Asthma Proceedings, 21, 21-24.
100. Metcalfe, D.D. & Akin, C. (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leukemia Research, 25, 577-582.
101. Mican, J.M., Di-Bisceglie, A.M., Fong, T.L., Travis, W.D., Kleiner, D.E., Baker, B. & Metcalfe, D.D. (1995) Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology, 22, 1163-1170.
102. Miner, P.B. (1991) The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. Journal of Investigative Dermatology, 96, 40S-43S.
103. Mitsui, H., Furitsu, T., Dvorak, A.M., Irani, A.M., Schwartz, L.B., Inagaki, N. et al. (1993) Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proceedings of the National Academy of Sciences of the USA, 90, 735-739.
104. Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y. & Metcalfe, D.D. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the USA, 92, 10560-10564.
105. Ochi, H., Hirani, W.M., Yuan, Q., Friend, D.S., Austen, K.F. & Boyce, J.A. (1999) T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. Journal of Experimental Medicine, 190, 267-280.
106. Oude-Elberink, J.N., de Monchy, J.G., Kors, J.W., van Doormaal, J.J. & Dubois, J.E. (1997) Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. Journal of Allergy and Clinical Immunology, 99, 153-154.
107. Parker, R.I. (1991) Hematologic aspects of mastocytosis. II. management of hematologic disorders in association with systemic mast cell disease. Journal of Investigative Dermatology, 96, 52S-53S.
108. Parwaresch, M.R., Horny, H.-P. & Lennert, K. (1985) Tissue mast cells in health and disease. Pathology Research Practicals, 179, 439-461.
109. Peachell, P.T. & Morcos, S.K. (1998) Effects or radiographic contrast media on histamine release from human mast cells and basophils. British Journal of Radiology, 71, 24-30.
110. Plaut, M., Pierce, J.H., Watson, C.J., Hanley-Hyde, J., Nordan, R.P. & Paul, W.E. (1989) Mast cell lines produce lymphokines in response to cross linkage of Fc epsilon RI or to calcium ionophores. Nature, 339, 64-67.
111. Prokocimer, M. & Polliack, A. (1981) Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. American Journal of Clinical Pathology, 75, 34-38.
112. Pulik, M., Lionnet, F., Petit, A., Genet, P. & Gaulier, A. (1994) Longterm response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. American Journal of Hematology, 47, 66.
113. Rafii, M., Firooznia, H., Golimbu, C. & Balthazar, E. (1983) Pathologic fracture in systemic mastocytosis, radiographic spectrum and review of the literature. Clinical Orthopedics, 180, 260-267.
114. Reisberg, I.R. & Oyakawa, S. (1987) Mastocytosis with malabsorption, myelofibrosis, and massive ascites. American Journal of Gastroenterology, 82, 54-60.
115. Roberts, L.J., Sweetman, B.J., Lewis, R.A., Austen, K.F. & Oates, J.A. (1980) Increased production of prostaglandin D2 in patients with systemic mastocytosis. New England Journal of Medicine, 303, 1400-1404.
116. Robin, J.L., Seldin, D.C., Austen, K.F. & Lewis, R.A. (1985) Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticoids. Journal of Immunology, 135, 2719-2726.
117. Roth, J., Brudler, O. & Henze, E. (1985) Functional asplenia in malignant mastocytosis. Journal of Nuclear Medicine, 26, 1149-1152.
118. - cell population. Blood, 84, 2489-2496.
119. Saito, H., Ebisawa, M., Sakaguchi, N., Onda, T., Iikura, Y., Yanagida, M., Uzumaki, H. & Nakahata, T. (1995) Characterization of cord-blood-derived human mast cells cultured in the presence of steel factor and interleukin-6. International Archives of Allergy and Immunology, 107, 63-65.
120. Schernthaner, G.H., Jordan, J.H., Ghannadan, M., Agis, H., Bevec, D., Nuñez, R., Escribano, L., Majdic, O., Willheim, M., Worda, C., Printz, D., Fritsch, G., Lechner, K. & Valent, P. (2001) Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood, 98, 3784-3792.
121. Schwartz, L.B. (1985) The mast cell. In: Allergy. Vol. 1. (ed. by A.P. Kaplan), pp. 53-92. Churchill Livingston, Edinburgh.
122. Schwartz, L.B. (2001) Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leukemia Research, 25, 553-562.
123. Schwartz, L.B. & Irani, A.M. (2000) Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematology Oncology Clinics of North America, 14, 641-657.
124. Schwartz, L.B., Metcalfe, D.D., Miller, J.S., Earl, H. & Sullivan, T. (1987) Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. New England Journal of Medicine, 316, 1622-1626.
125. Schwartz, L.B., Sakai, K., Bradford, T.R., Ren, S., Zweiman, B., Worobec, A.S. & Metcalfe, D.D. (1995) The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Journal of Clinical Investigation, 96, 2702-2710.
126. Scott, Jr, H.W., Parris, W.C., Sandidge, P.C., Oates, J.A. & Roberts, II, L.J. (1983) Hazards in operative management of patients with systemic mastocytosis, Annals of Surgery, 197, 507-514.
127. Serafin, W.E. & Austen, K.F. (1987) Mediators of immediate type hypersensitivity reactions. New England Journal of Medicine, 317, 30-34.
128. Simmons, P.J., Aylett, G.W., Niutta, S., To, L.B., Juttner, C.A. & Ashman, L.K. (1994) c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Experimental Hematology, 22, 157-165.
129. Soter, N.A., Austen, K.F. & Wassermann, S.I. (1979) Oral disodium cromoglycate in the treatment of systemic mastocytosis. New England Journal of Medicine, 301, 465-469.
130. Sotlar, K., Marafioti, T., Griesser, H., Theil, J., Aepinus, C., Jaussi, R., Stein, H., Valent, P. & Horny, H.-P. (2000) Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Molecular Pathology, 53, 188-193.
131. Sperr, W.R., Walchshofer, S., Horny, H.-P., Födinger, M., Simonitsch, I., Fritsche-Polanz, R., Schwarzinger, I., Tschachler, E., Sillaber, C., Hagen, W., Geissler, K., Chott, A., Lechner, K. & Valent, P. (1998) Systemic mastocytosis associated with acute myeloid leukemia: report of two cases and detection of the c-kit mutation Asp-Val 816. British Journal of Haematology, 103, 740-749.
132. Sperr, W.R., Horny, H.-P., Lechner, K. & Valent, P. (2000) Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leukemia and Lymphoma, 37, 473-486.
133. Sperr, W.R., Jordan, J.H., Baghestanian, M., Kiener, H.P., Samorapoompichit, P., Semper, H., Hauswirth, A., Schernthaner, G.H., Chott, A., Natter, S., Kraft, D., Valenta, R., Schwartz, L.B., Geissler, K., Lechner, K. & Valent, P. (2001a) Expression of mast cell tryptase in myeloblasts in a group of patients with acute myeloid leukemia. Blood, 98, 2200-2209.
134. Sperr, W.R., Escribano, L., Jordan, J.H., Schernthaner, G.H., Kundi, M., Horny, H.-P. & Valent, P. (2001b) Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leukemia Research, 25, 529-536.
135. Sperr, W.R., Jordan, J.H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Honry, H.-P. & Valent, P. (2002a) Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. International Archives of Allergy and Immunology, 128, 136-141.
136. Sperr, W.R., Stehberger, B., Wimazal, F., Baghestanian, M., Schwartz, L.B., Kundi, M., Semper, H., Jordan, J.H., Chott, A., Drach, J., Jäger, U., Geissler, K., Greschniok, A., Horny, H.P., Lechner, K. & Valent, P. (2002b) Serum tryptase measurements in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 43, 1097-1105.
137. Stellato, C. & Marone, G. (1995) Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chemical Immunology, 62, 108-131.
138. Stellato, C., de Paulis, A., Cirillo, R., Mastronardi, P., Mazarrella, B. & Marone, G. (1991) Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology, 74, 1078-1086.
139. Stellato, C., Cirillo, R., de Paulis, A., Casolaro, V., Patella, V., Mastronardi, P., Mazzarella, B. & Marone, G. (1992) Human baspohil/mast cell releasability. IX. heterogeneity of the effects of opioids on mediator release. Anesthesiology, 77, 932-940.
140. Stellato, C., de Crescenzo, G., Patella, V., Mastronardi, P., Mazzarella, B. & Marone, G. (1996) Human basophil/mast cell releasability. XI. heterogeneity of the effects of contrast media on mediator release. Journal of Allergy and Clinical Immunology, 97, 838-850.
141. Tefferi, A., Li, C.Y., Butterfield, J.H. & Hoagland, H.C. (2001) Treatment of systemic mast-cell disease with cladribine. New England Journal of Medicine, 344, 307-309.
142. Travis, W.D. & Li, C.Y. (1988) Pathology of the lymph node and spleen in systemic mast cell disease. Modern Pathology, 1, 4-14.
143. Travis, W.D., Li, C.Y., Hogaland, H.C., Travis, L.B. & Banks, P.M. (1986) Mast cell leukemia: report of a case and review of the literature. Mayo Clinic Proceedings, 61, 957-966.
144. Travis, W.D., Li, C.Y., Bergstralh, E.J., Yam, L.T. & Swee, R.G. (1988a) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine, 67, 345-368.
145. Travis, W.D., Li, C.Y., Yam, L.T., Bergstralh, E.J. & Swee, R.G. (1988b) Significance of systemic mast cell disease with associated hematologic disorders. Cancer, 62, 965-972.
146. Valent, P. (1994) The riddle of the mast cell: kit (CD117)-ligand as the missing link? Immunology Today, 15, 111-114.
147. Valent, P. (1996) Biology, classification and treatment of human mastocytosis. Wiener Klinische Wochenschrift, 108, 385-397.
148. Valent, P. & Bettelheim, P. (1992) Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Advances of Immunology, 52, 333-423.
149. Valent, P., Ashman, L.K., Hinterberger, W., Eckersberger, F., Majdic, O., Lechner, K. & Bettelheim, P. (1989) Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood, 73, 1778-1785.
150. Valent, P., Spanblöchl, E., Sperr, W.R., Sillaber, C., Zsebo, K.M., Agis, H., Strobl, H., Geissler, K., Bettelheim, P. & Lechner, K. (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit ligand in long term culture. Blood, 80, 2237-2245.
151. Valent, P., Escribano, L., Parwaresch, R., Schemmel, V., Schwartz, L.B., Sotlar, K., Sperr, W.R. & Horny, H.-P. (1999) Recent advances in mastocytosis research. International Archives of Allergy and Immunology, 120, 1-7.
152. Valent, P., Horny, H.-P., Escribano, L., Longley, B.J., Li, C.Y., Schwartz, L.B., Marone, G., Nunez, R., Akin, C., Sotlar, K., Sperr, W.R., Wolff, K., Brunning, R.D., Parwaresch, R.M., Austen, K.F., Lennert, K., Metcalfe, D.D., Vardiman, J.W. & Bennett, J.M. (2001a) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 25, 603-625.
153. Valent, P., Sperr, W.R., Samorapoompichit, P., Geissler, K., Lechner, K., Horny, H.-P. & Bennett, J.M. (2001b) Myelomastocytic overlap syndromes: Biology, criteria, and relationship to mastocytosis. Leukemia Research, 25, 595-602.
154. Valent, P., Horny, H.-P., Li, C.Y., Longley, J.B., Metcalfe, D.D., Parwaresch, R.M. & Bennett, J.M. (2001c) Mastocytosis (mast cell disease). In: World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, Vol. 1 (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman). pp. 291-302. WHO, Geneva.
155. Valent, P., Akin, C., Sperr, W.R., Horny, H.-P. & Metcalfe, D.D. (2002a) Smouldering mastocytosis: a new type of systemic mastocytosis with slow progression. International Archives of Allergy and Immunology, 127, 137-139.
156. Valent, P., Samorapoompichit, P., Sperr, W.R., Horny, H.-P. & Lechner, K. (2002b) Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematology Journal, 3, 90-94.
157. Valent, P., Akin, C., Sperr, W.R. Escribano, L., Arock, M., Horny, H.P., Bennett, J.M. & Metcalfe, D.D. (2003) Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leukemia Research, 27, 635-641.
158. Weide, R., Ehlenz, K., Lorenz, W., Walthers, E., Klausmann, M. & Pfluger, K.H. (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Annals of Hematology, 72, 41-43.
159. Wershil, B.K., Furuta, G.T., Lavigne, J.A., Choudhury, A.R., Wang, Z.S. & Galli, S.J. (1995) Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse. Journal of Immunology, 154, 1391-1398.
160. Wimazal, F., Sperr, W.R., Horny, H.-P., Carroll, V., Binder, B.R., Fonatsch, C., Walchshofer, S., Födinger, M., Schwarzinger, L. Samorapoompichit, S., Chott, A., Dvorak, A.M., Lechner, K. & Valent, P. (1999) Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. American Journal of Hematology, 61, 66-77.
161. Wimazal, F., Jordan, J.H., Sperr, W.R., Chott, A., Dabbass, S., Lechner, K., Horny, H.-P. & Valent, P. (2002) Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. American Journal of Pathology, 160, 1639-1645.
162. Wodnar-Filipowicz, A., Heusser, C.H. & Moroni, C. (1989) Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature, 339, 150-152.
163. Wolff, K. (2002) Treatment of cutaneous mastocytosis. International Archives of Allergy and Immunology, 127, 156-159.
164. Wolff, K., Komar, M. & Petzelbauer, P. (2001) Clinical and histopathological aspects of cutaneous mastocytosis. Leukemia Research, 25, 519-528.
165. Worobec, A.S. (2000) Treatment of systemic mast cell disorders. Hematology Oncology Clinics of North America, 14, 659-687.
166. Worobec, A.S. & Metcalfe, D.D. (2002) Mastocytosis: current treatment concepts. International Archives of Allergy and Immunology, 127, 153-155.
167. Worobec, A.S., Kirshenbaum, A.S., Schwartz, L.B. & Metcaffe, D.D. (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leukemia and Lymphoma, 22, 501-508.
168. Yaniv, R., Segal, E. & Perel, A. (1992) Anesthetic considerations in mast-cell proliferative disease (mastocytosis). Harefuah, 122, 780-784.
169. Yavuz, A.S., Lipsky, P.E., Yavuz, S., Metcalfe, D.D. & Akin, C. (2002) Evidence for the involvement of an hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutations in the c-kit gene. Blood, 100, 661-665.